双特异性抗体-话题@MedSci

#双特异性抗体#

22篇内容 | 5038人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=802886, encodeId=5d2780288673, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>双特异性抗体，现在越来越普及了。, objectTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, objectType=article, longId=197588, objectId=c63a19e588ba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/Immunology_1.jpg, objectUrl=/article/show_article.do?id=c63a19e588ba, replyNumber=0, likeNumber=211, createdTime=2020-07-15, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c63a19e588ba, moduleTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c63a19e588ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=602168, encodeId=a0db602168be, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>CR率很高, objectTitle=EHA 2020：罗氏的CD20xCD3双特异性抗体glofitamab治疗淋巴瘤的最新进展, objectType=article, longId=195825, objectId=27f019582522, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200610/f65dd8718d374606a8c66a5b440911d9.jpg, objectUrl=/article/show_article.do?id=27f019582522, replyNumber=0, likeNumber=215, createdTime=2020-06-13, rootId=0, userName=lifefamily@163, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f019582522, moduleTitle=EHA 2020：罗氏的CD20xCD3双特异性抗体glofitamab治疗淋巴瘤的最新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f019582522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=602067, encodeId=f37460206e2f, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>🔥到不行了, objectTitle=双特异性抗体中外百家争先，300亿蛋糕将入谁家？, objectType=article, longId=195729, objectId=a658195e29a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200610/9d743ad5420d4d1eb0daf0ced2a95cbc.jpg, objectUrl=/article/show_article.do?id=a658195e29a1, replyNumber=0, likeNumber=212, createdTime=2020-06-11, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a658195e29a1, moduleTitle=双特异性抗体中外百家争先，300亿蛋糕将入谁家？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a658195e29a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=601990, encodeId=bfa2601990a0, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>最担心的是毒性，疗效没的说, objectTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, objectType=article, longId=195642, objectId=43db195642e7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/CellMotility_1.jpg, objectUrl=/article/show_article.do?id=43db195642e7, replyNumber=1, likeNumber=225, createdTime=2020-06-10, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db195642e7, moduleTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43db195642e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=601446, encodeId=90a16014462d, content=<a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>PD-1/TGF-beta 双抗有戏, objectTitle=免疫治疗耐药？新联合疗法，有望克服PD-1免疫疗法耐药, objectType=article, longId=195305, objectId=e6621953051a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200603/1620165040324827bc7205b143df5276.jpg, objectUrl=/article/show_article.do?id=e6621953051a, replyNumber=0, likeNumber=223, createdTime=2020-06-04, rootId=0, userName=lifefamily@163, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6621953051a, moduleTitle=免疫治疗耐药？新联合疗法，有望克服PD-1免疫疗法耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6621953051a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

双特异性抗体

2020-05-29

lovetcm (审核中...)

前往app查看评论内容

#双特异性抗体#双特异性抗体，现在越来越普及了。

罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定

2020-07-15

lifefamily@163 (审核中...)

前往app查看评论内容

#双特异性抗体#CR率很高

EHA 2020：罗氏的CD20xCD3双特异性抗体glofitamab治疗淋巴瘤的最新进展

2020-06-13

lovetcm (审核中...)

前往app查看评论内容

#双特异性抗体#🔥到不行了

双特异性抗体中外百家争先，300亿蛋糕将入谁家？

2020-06-11

lovetcm (审核中...)

前往app查看评论内容

#双特异性抗体#最担心的是毒性，疗效没的说

合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元

2020-06-10

lifefamily@163 (审核中...)

前往app查看评论内容

#双特异性抗体#PD-1/TGF-beta 双抗有戏

免疫治疗耐药？新联合疗法，有望克服PD-1免疫疗法耐药

2020-06-04

科室
- - 订阅+
  - 更多科室
工具
服务